 Connection
Max Seibold to Treatment Outcome
This is a "connection" page, showing publications Max Seibold has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.034 |
|
|
|
-
McGeachie MJ, Sordillo JE, Dahlin A, Wang AL, Lutz SM, Tantisira KG, Panganiban R, Lu Q, Sajuthi S, Urbanek C, Kelly R, Saef B, Eng C, Oh SS, Kho AT, Croteau-Chonka DC, Weiss ST, Raby BA, Mak ACY, Rodriguez-Santana JR, Burchard EG, Seibold MA, Wu AC. Expression of SMARCD1 interacts with age in association with asthma control on inhaled corticosteroid therapy. Respir Res. 2020 Jan 28; 21(1):31.
Score: 0.017
-
Gould W, Peterson EL, Karungi G, Zoratti A, Gaggin J, Toma G, Yan S, Levin AM, Yang JJ, Wells K, Wang M, Burke RR, Beckman K, Popadic D, Land SJ, Kumar R, Seibold MA, Lanfear DE, Burchard EG, Williams LK. Factors predicting inhaled corticosteroid responsiveness in African American patients with asthma. J Allergy Clin Immunol. 2010 Dec; 126(6):1131-8.
Score: 0.009
-
Jin Y, Hu D, Peterson EL, Eng C, Levin AM, Wells K, Beckman K, Kumar R, Seibold MA, Karungi G, Zoratti A, Gaggin J, Campbell J, Galanter J, Chapela R, Rodr?guez-Santana JR, Watson HG, Meade K, Lenoir M, Rodr?guez-Cintr?n W, Avila PC, Lanfear DE, Burchard EG, Williams LK. Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients. J Allergy Clin Immunol. 2010 Sep; 126(3):618-25.e1-2.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|